🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Without clinical trials there are no treatments. Without clinical trials that enroll a diverse population we don’t know how drugs work in different people.

That's the world's literature on ivermectin in advanced cancer. 8 pts with TNBC getting ICI + ivermectin, 1 response (same rate as ICI alone, in other trials), avg PFS of 2.5 m. So, at present, there is no evidence for meaningful clinical activity of ivermectin in cancer.

With ASCENT-03 and -04, sacituzumab is moving in for 1st line mTNBC. Posing similar questions with more frequent use of ADCs…sequencing, PFS2, toxicity, QoL

Thematic take on ASCO breast cancer abstracts: 1. Move 'em up. DB09, ASCENT-04, SERENA-6 are really just trials of using agents earlier in the course of advanced disease. Since all patients with the right tumor subtype will eventually get the agent, the only real question is:

🔥 #ASCO25 Re-challange with Trastuzumab Deruxtecan after grade 1 ILD is overall safe in a real-world population Some of these patients did not recover completely to grade 0 before re-challange Great presentation from Hope Rugo reassuring on ILD management in RWD

More evidence for the value of cdk4/6 inhibitor in 1L patients with triple positive (ER+/HER2+) breast cancer. -ORR 61% with a non chemo containing regimen -mPFS 30 months

Building off of Nancy Lin, MD and Dr Pablo Leone’s data with carboplatin/bevacizumab in brain metastases. 77% intracranial response rate of carbo, bev, and PD-1 inhibition in TNBC brain metastases shows excellent potential. Time to try this with bispecifics. #bcsm #ASCO25

Rapid oral mBC #ASCO25 OptiTROP-Breast05: Sac-TMT shows 70% ORR and 13.4 mo PFS as 1st-line therapy in advanced TNBC (incl. pts with PD-L1–negative, CPS <10). Promising efficacy with no neuropathy or ILD. 2 phase III trials now underway in PD-L1–negative mTNBC. OncoAlert

Great discussion by Dr Clark ASCO Some thoughts ⭐️inavo/Palbo/fulv clear 1st line in ET refractory PIK3caM mBC - now w/ sig OS benefit ❓not sure what ipatasertib adds to landscape as Capiversatib seems to have better PFS and OS difference with similar SE profile #ASCO25

Dr Kim presented results showing oral paclitaxel vs IV paclitaxel in MBC w/ similar PFS/OS ⭐️differences in SE - more GI tox & neutropenia in PO taxol but less neuropathy and reactions ❗️oral tx regimens for pts means no need for a port, less clinic visits ASCO #asco25 #bcsm

Our Duke breast onc family at ASCO ❤️ ASCO Duke Cancer Heather Moore Carey Anders Marija Sullivan, MD

Feeling incredibly grateful to be joining this amazing group of breast oncology colleagues at Duke this fall! 💙#ASCO25

Key point! Intensive ctDNA screening for every patient when only 10% were eligible to switch? Interested to see the data and discussion later today ASCO #bcsm

1000% agree - Angie DeMichele, MD, MSCE, FASCO broke down each point so well and gave great insights on how we should think about this data and its potential limitations in clinical practice right now ASCO #bcsm

DB-09 📣by Sara Tolaney TDxd + P vs THP Great review by Dr. Isaacs of results we need QOL data especially for pts on maintenance HP vs TDxd, we know clinically that there is MUCH more tox w/ TDxd & many pts experience great QOL on HP maintenance therapy ASCO #bcsm

Agree! Also if we think in real world for our pts - maintenance HP (esp now we have a subq option) allow pts to not need a port, less frequent labs, less time spent in infusion, more time outside of cancer center Looking forward to hearing pt perspectives! GRASP ASCO

Very exciting!!! We need new drugs especially in mTNBC and especially post topo-1 ADCs as they move further up in our treatment paradigm

Oral abstract early #BreastCancer session at #ASCO25: do we really need #carboplatin with neoadjuvant #taxane #trastuzumab #pertuzumab in #HER2+ disease? Very promising findings but survival outcomes are needed OncoAlert ASCO #bcsm

After recurrence, the median duration of first-line metastatic treatment was 3.0 months (IQR 1.6-5.0 months)…we need to identify best systemic therapy options for those recurring on adjuvant CDK4/6i!

Recent rationale in metastatic breast cancer for bringing ADCs into the 1st line has quoted very high 1st line attrition rates of patients not making it to second line. This study is likely more accurate of 2025 patients. In total, 9% of patients with MBC do not make it to